• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy.脱水羊膜贴片用于治疗继发于 mirvetuximab soravtansine-gynx（MIRV）治疗的眼部事件。
Gynecol Oncol Rep. 2024 Nov 19;56:101547. doi: 10.1016/j.gore.2024.101547. eCollection 2024 Dec.
2
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.FRα 高表达铂类敏感型卵巢癌患者中，采用 mirvetuximab soravtansine 联合贝伐珠单抗维持治疗对比贝伐珠单抗单药维持治疗的疗效。
Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31.
3
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.MIRASOL试验的患者报告结局：评估mirvetuximab soravtansine与化疗治疗叶酸受体α阳性、铂耐药卵巢癌患者的疗效，一项随机、开放标签的3期试验。
Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X.
4
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.珐瑯质蛋白相关细胞黏附分子阳性、铂类耐药卵巢癌中的 Mirvetuximab Soravtansine。
N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169.
5
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.III 期随机临床试验：索拉非尼单药治疗与化疗用于铂耐药卵巢癌患者的比较：FORWARD I 研究的主要分析。
Ann Oncol. 2021 Jun;32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. Epub 2021 Mar 2.
6
Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.预防和管理与mirvetuximab soravtansine相关的眼部事件的策略。
Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. eCollection 2023 Jun.
7
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.米拉妥昔单抗soravtansine-gynx：晚期或复发性卵巢癌的抗体/抗原药物偶联物（ADC）。
Int J Gynecol Cancer. 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924.
8
A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer.mirvetuximab soravtansine-gynx用于治疗叶酸受体α表达的铂耐药卵巢癌的综述
Am J Health Syst Pharm. 2025 May 21;82(10):522-536. doi: 10.1093/ajhp/zxaf011.
9
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.mirvetuximab soravtansine治疗FRα阳性、三线及以上复发铂敏感卵巢癌的疗效和安全性：单臂II期PICCOLO试验
Ann Oncol. 2025 Mar;36(3):321-330. doi: 10.1016/j.annonc.2024.11.011. Epub 2024 Nov 29.
10
Mirvetuximab after anaphylaxis to Paclitaxel: A case report.对紫杉醇过敏后使用 mirvetuximab：一例病例报告。
Gynecol Oncol Rep. 2024 Jul 6;54:101452. doi: 10.1016/j.gore.2024.101452. eCollection 2024 Aug.

本文引用的文献

1
Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis.FRa 阳性表达的复发性卵巢癌中 mirvetuximab soravtansine 的疗效和安全性：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2024 Feb;194:104230. doi: 10.1016/j.critrevonc.2023.104230. Epub 2023 Dec 18.
2
Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.预防和管理与mirvetuximab soravtansine相关的眼部事件的策略。
Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. eCollection 2023 Jun.
3
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.ADC毒性机制及提高ADC耐受性的策略。
Cancers (Basel). 2023 Jan 24;15(3):713. doi: 10.3390/cancers15030713.
4
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.高叶酸受体α表达的铂耐药卵巢癌患者中 Mirvetuximab Soravtansine 的疗效和安全性：来自 SORAYA 研究的结果。
J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30.
5
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates.与抗体药物偶联物相关的屈光变化和角膜曲率变化。
Cornea. 2022 Jun 1;41(6):792-801. doi: 10.1097/ICO.0000000000002934. Epub 2021 Nov 23.
6
Amniotic Membrane Transplantation in Ophthalmology: An Updated Perspective.眼科羊膜移植：最新观点
Clin Ophthalmol. 2020 Jul 22;14:2057-2072. doi: 10.2147/OPTH.S208008. eCollection 2020.
7
Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.生物制剂、靶向药物和传统化疗药物已知的和新出现的眼部毒性。
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.
8
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.抗体偶联药物 Mirvetuximab Soravtansine 诱导的角膜异常的皮质类固醇预防性滴眼治疗的评价。
Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.
9
Ocular Toxicity of Mirvetuximab.米维妥昔单抗的眼部毒性
Cornea. 2019 Feb;38(2):229-232. doi: 10.1097/ICO.0000000000001805.
10
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.mirvetuximab soravtansine（IMGN853），一种靶向叶酸受体α的抗体药物偶联物，在实体瘤患者中的1期剂量递增研究。
Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25.

脱水羊膜贴片用于治疗继发于 mirvetuximab soravtansine-gynx（MIRV）治疗的眼部事件。

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy.

作者信息

File Brittany, Hari Anjali, Bei Ling

机构信息

Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA, USA.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.

出版信息

Gynecol Oncol Rep. 2024 Nov 19;56:101547. doi: 10.1016/j.gore.2024.101547. eCollection 2024 Dec.

DOI:10.1016/j.gore.2024.101547
PMID:39640287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11617700/
Abstract

•Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid and lubricating drops.•Dehydrated amniotic membrane patch to treat MIRV related ocular events is a novel therapeutic option.

摘要

• mirvetuximab soravtansine（MIRV）用于治疗FRα阳性、铂耐药的上皮性卵巢癌。

• MIRV与眼部事件相关，导致化疗剂量延迟、剂量减少和中断。

• 历史上，预防治疗中断的缓解策略依赖于皮质类固醇和润滑滴眼液。

• 脱水羊膜贴片治疗MIRV相关眼部事件是一种新的治疗选择。